Transcenta

Gastric cancer
#Antibody #FDA #Gastrointestinal #Oncology #Phase III trial #Stomach cancer #Transcenta

Antibody for gastric cancer progresses to Phase III trials

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in… Read More

#Cancer Research #News #Regulatory